# US 2015/0148415 A1 · Derivatized dendrimer with low citotoxicity for in vivo, ex vivo, in vitro or in situ chelation of heavy metals or actinides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148415 A1
- Document ID: US20150148415A1
- Status: Published application
- Kind: A1
- Application number: 14/087,727
- Filed: 2013-11-22
- Published: 2015-05-28
- Earliest claimed: 2013-11-22
- Applicants: Fundacion Fraunhofer Chile Research; Universidad De Talca
- Inventors: Leonardo SILVA SANTOS; Rainer FISCHER; Luis GUZMAN; Fabiane M. NACHTIGALL
- Web page: https://patentgrep.com/patent/US20150148415A1

## CPC

- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention considers derivatized nanomolecules with proven effectiveness to bind to actinides, more specifically uranium, during in vivo, ex vivo, in vitro or in situ assays. When assayed in vivo, the invention showed a reduction in at least kidney damage due to exposition to uranium.

## Claims

### Claim 1

Derivatized dendrimer with low citotoxicity for in vivo, ex vivo, in vitro or in situ chelation of heavy metals or actinides, comprising a polyamidoamine (PAMAM) dendrimers derivatized with an amino acid and a terminal functional group.

### Claim 2 (depends on 1)

The derivatized dendrimer according to claim 1, wherein the amino acid is a basic amino acid.

### Claim 3 (depends on 1)

The derivatized dendrimer according to claim 1, wherein the amino acid is selected among histidine, lysine, or arginine.

### Claim 4 (depends on 1)

The derivatized dendrimer according to claim 1, wherein the terminal functional group is a carbamate.

### Claim 5 (depends on 4)

The derivatized dendrimer according to claim 4, wherein the terminal functional group is a carboxybenzyl group.

### Claim 6 (depends on 1)

The derivatized dendrimer according to claim 1, wherein the terminal functional group is a tosyl group.

### Claim 7 (depends on 1)

The derivatized dendrimer according to claim 1, wherein the derivatized PAMAM dendrimers are of generations 2nd, 3rd, 4th, 5th, or 6th.

### Claim 8 (depends on 1)

The derivatized dendrimer according to claim 1, wherein the derivatized PAMAM dendrimers are of generations 0.5, 1.5, 2.5, 3.5, 4.5.

### Claim 9 (depends on 1)

Pharmaceutical composition for treating a blood clotting disorder comprising at least one derivatized dendrimer according to claim 1, a suitable solvate, suitable salts, and or excipients.

### Claim 10 (depends on 1)

Method for treating exposure of a subject to a heavy metal or acitinide, comprising the administration of a pharmaceutical composition comprising at least one of molecules according to claim 1, to a patient in need thereof.

### Claim 11 (depends on 1)

Method for removal of heavy metals or actinides from a liquid solution, comprising the use of immobilized molecules according to claim 1 to a suitable matrix, and exposing the liquid solution to said matrix containing said immobilized molecules.
